Victory Capital Management’s Niagen Bioscience NAGE Stock Holding History

Victory Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51M	Buy	473,372 +47,950	+11%	+$195K	﹤0.01%	1719
2026 Q1	$1.88M	Buy	425,422 +105,010	+33%	+$567K	﹤0.01%	1615
2025 Q4	$2.04M	Sell	320,412 -58,581	-15%	-$408K	﹤0.01%	1583
2025 Q3	$3.54M	Sell	378,993 -28,639	-7%	-$289K	﹤0.01%	1437
2025 Q2	$5.87M	Buy	407,632 +184,953	+83%	+$1.83M	﹤0.01%	1262
2025 Q1	$1.54M	Buy	+222,679	New	+$1.4M	﹤0.01%	1614

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Victory Capital Management's NAGE Position: Q2 2026 in Review

Victory Capital Management increased its Niagen Bioscience (NAGE) stake by 11% in Q2 2026, buying an estimated $195K and bringing the position to 473,372 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1719.

Victory Capital Management first reported a position in NAGE in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.87M in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

Victory Capital Management held 473,372 shares of Niagen Bioscience worth $1.51M as of Q2 2026.
Victory Capital Management bought 47,950 Niagen Bioscience shares in Q2 2026, an estimated $195K.
Niagen Bioscience made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1719 holding.
Victory Capital Management first reported a position in Niagen Bioscience in Q1 2025 and has held it in 6 quarters since.
Victory Capital Management's Niagen Bioscience position peaked at $5.87M in Q2 2025.
140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.